Platelet dysfunction detected at high shear in patients with heart valve disease

被引:23
作者
Francis, JL [1 ]
机构
[1] Florida Hosp, Walt Disney Mem Canc Inst, Ctr Hemostasis & Thrombosis, Orlando, FL 32804 USA
关键词
platelets; platelet function analyzer; cardiovascular surgery; valvular disease;
D O I
10.1080/095371000403062
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Whether patients with valvular heart disease have a defect of platelet function has been unclear, Despite evidence that these individuals have an abnormality detectable only under conditions of high shear stress, no methods have been widely available to adequately assess platelet function under such conditions. The Platelet Function Analyzer (PFA)-100(R) measures platelet function in a high shear environment and is well suited to the detection of platelet dysfunction in the clinical laboratory. The instrument records the time for platelets to occlude a membrane coated with collagen and either epinephrine (CEPI) or ADP (CADP), We studied the PFA-100(R) in 398 patients before open heart surgery; 308 for coronary artery bypass grafting (CABG) and 90 for aortic or mitral valve replacement (VR), Patients were classified as normal (CEPI less than or equal to 153 s); 'aspirin effect' (CEPI>153 s but CADP less than or equal to 109 s) or abnormal (CEPI>153 s and CADP>109 s), In the CABG group, 41.2% were classified as normal, 43.2% as 'aspirin effect' and 15.6% as abnormal. In contrast, in patients undergoing VR, these values were 6.7, 11.1 and 82.4%, respectively. Patients with valvular disease had significantly longer closure times for both CEPI and CADP tests (P<0.001). In addition, the valvular disease group had a significantly higher proportion of patients with markedly prolonged (>150s) closure times in the CADP cartridge (43.3 vs. 3.6%, respectively). Only one (0.3%) patient in the CABG group had non-closure (>300 s) in the CADP test compared to seven (7.8%) in the valvular disease group. Three of six patients in the latter group bled excessively during surgery, We conclude that abnormal CADP closure is much more frequent among patients with aortic or mitral valve disease compared to those with coronary artery disease. This may reflect pre-existing high-shear damage to platelets that renders them refractory to subsequent shear activation and aggregation in the PFA-100(R) system. Further studies are needed to more precisely define the platelet defect in these patients, Markedly prolonged CADP closure in patients with valvular disease may indicate an increased likelihood of intra-operative bleeding, although an appropriately designed prospective study is needed to adequately address this hypothesis.
引用
收藏
页码:133 / 136
页数:4
相关论文
共 20 条
  • [1] THE BLEEDING-TIME AS A PREOPERATIVE SCREENING-TEST
    BARBER, A
    GREEN, D
    GALLUZZO, T
    TSAO, CH
    [J]. AMERICAN JOURNAL OF MEDICINE, 1985, 78 (05) : 761 - 764
  • [2] BRANDT CM, 1992, ACTA CARDIOL, V47, P271
  • [3] BURNS ER, 1989, ARCH PATHOL LAB MED, V113, P1219
  • [4] BUTLER J, 1992, J CARDIOVASC SURG, V33, P33
  • [5] PLATELET ACTIVATION AND MITRAL-VALVE PROLAPSE
    FISHER, M
    WEINER, B
    OCKENE, IS
    FORSBERG, A
    DUFFY, CP
    LEVINE, PH
    [J]. NEUROLOGY, 1983, 33 (03) : 384 - 386
  • [6] Can the Platelet Function Analyzer (PFA®)-100 test substitute for the template bleeding time in routine clinical practice?
    Francis, J
    Francis, D
    Larson, L
    Helms, E
    Garcia, M
    [J]. PLATELETS, 1999, 10 (2-3) : 132 - 136
  • [7] Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases
    Fressinaud, E
    Veyradier, A
    Truchaud, F
    Martin, I
    Boyer-Neumann, C
    Trossaert, M
    Meyer, D
    [J]. BLOOD, 1998, 91 (04) : 1325 - 1331
  • [8] GohlkeBarwolf C, 1996, ACTA CARDIOL, V51, P129
  • [9] Performance of the platelet function analyser PFA-100® in testing abnormalities of primary haemostasis
    Harrison, P
    Robinson, MSC
    Mackie, IJ
    Joseph, J
    McDonald, SJ
    Liesner, R
    Savidge, GF
    Pasi, J
    Machin, SJ
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (01) : 25 - 31
  • [10] LIN SL, 1989, CAN J CARDIOL, V5, P84